Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07132125 · ClinicalTrials.gov registry record · NA
Conversations With AI Chatbots Increase Short-Term Vaccine Intentions But Do Not Outperform Standard Public Health Messaging
A NA study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 930
- Enrollment target
NCT07132125: Completed NA study, sponsored by University of Pennsylvania.
NCT07132125 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 930 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07132125, a NA study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 930 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to test whether short conversations with large language model (LLM) chatbots can persuade vaccine-hesitant parents to vaccinate their children against human papillomavirus (HPV). The study compares two chatbot styles to official public health information and to a no-message control. Parents of HPV-eligible children first complete a survey about their attitudes toward the HPV vaccine and their main concerns. They are then randomly assigned to read public health materials, have a three-minute conversation with either a default-style chatbot or a conversational-style chatbot tailored to their concern, or receive no message. The main outcome is change in intent to vaccinate immediately after the intervention, with follow-up surveys at 15 and 45 days.
Primary Outcome
Self-reported likelihood, on a 0-100 scale, of vaccinating the participant's youngest HPV vaccine-eligible child (identified in pre-survey) within the next 12 months. Measured before and immediately after the intervention to assess short-term changes in vaccination intent.
Interventions
- BEHAVIORAL Default-style LLM chatbot
- BEHAVIORAL Conversational-style LLM chatbot
- BEHAVIORAL Public health informational materials
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 930 participants |
| Start Date | 2025-03-17 |
| Est. Completion | 2025-05-22 |
| Phase | NA |
What the finished NCT07132125 record still lists
NCT07132125 is an interventional study that assigns participants to a tested intervention. The registered 930 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 3 interventions - of which Default-style LLM chatbot is the first listed.
NCT07132125 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07132125 about?
NCT07132125 is a clinical study titled "Conversations With AI Chatbots Increase Short-Term Vaccine Intentions But Do Not Outperform Standard Public Health Messaging". The goal of this clinical trial is to test whether short conversations with large language model (LLM) chatbots can persuade vaccine-hesitant parents to vaccinate their children against human papillomavirus (HPV). The study compares two chatbot styles to official public health information and to a n...
What is the current status of trial NCT07132125?
This trial is currently completed. It is a NA study. The enrollment target is 930 participants. The study started on 2025-03-17. Estimated completion is 2025-05-22.
What interventions are being tested in trial NCT07132125?
The interventions under investigation include: Default-style LLM chatbot (BEHAVIORAL), Conversational-style LLM chatbot (BEHAVIORAL), Public health informational materials (BEHAVIORAL).
Who is sponsoring clinical trial NCT07132125?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07132125's enrollment target sits among peer trials
930 123rd of 2000 higher than 1,878 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05216432 · 930 participants · Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- NCT06932029 · 930 participants · NA
SMBP Study: Improving High Blood Pressure in Older Adults With Multiple Chronic Diseases
- NCT07235085 · 930 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
- NCT06555029 · 929 participants · NA
Oral Health Intervention in Adult Primary Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI